Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan
Abstract
:1. Introduction
2. Methods
2.1. Study Design
2.2. Participants
2.3. Assessment of IFG and Diabetes
2.4. Measurements of SARS-CoV-2 Spike Antibody Titers
2.5. Assessment of Covariates
2.6. Statistical Analysis
3. Results
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- WHO. World Health Organization Coronavirus Disease 2019 (COVID-19) Situation Report. Available online: https://covid19.who.int/ (accessed on 14 February 2022).
- Gregory, J.M.; Slaughter, J.C.; Duffus, S.H.; Smith, T.J.; LeStourgeon, L.M.; Jaser, S.S.; McCoy, A.B.; Luther, J.M.; Giovannetti, E.R.; Boeder, S.; et al. COVID-19 severity is tripled in the diabetes community: A prospective analysis of the pandemic’s impact in Type 1 and Type 2 diabetes. Diabetes Care 2021, 44, 526–532. [Google Scholar] [CrossRef] [PubMed]
- WHO. Cornavirus (COVID-19) Vaccinations. Available online: https://ourworldindata.org/covid-vaccinations# (accessed on 14 February 2022).
- Berbudi, A.; Rahmadika, N.; Tjahjadi, A.I.; Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr. Diabetes Rev. 2020, 16, 442–449. [Google Scholar] [CrossRef] [PubMed]
- Graves, D.T.; Kayal, R.A. Diabetic complications and dysregulated innate immunity. Front. Biosci. 2008, 13, 1227–1239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef] [PubMed]
- Thomas, S.J.; Moreira, E.D.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Polack, F.P.; Zerbini, C.; et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N. Engl. J. Med. 2021, 385, 1761–1773. [Google Scholar] [CrossRef]
- Saciuk, Y.; Kertes, J.; Mandel, M.; Hemo, B.; Stein, N.S.; Zohar, A.E. Pfizer-BioNTech vaccine effectiveness against SARS-CoV-2 infection: Findings from a large observational study in Israel. Prev. Med. 2022, 155, 106947. [Google Scholar] [CrossRef]
- Soetedjo, N.N.M.; Iryaningrum, M.R.; Lawrensia, S.; Permana, H. Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review. Diabetes Metab. Syndr. 2022, 16, 102406. [Google Scholar] [CrossRef]
- Ali, H.; Al-Terki, A.; Sindhu, S.; Alahmad, B.; Hammad, M.; Al-Sabah, S.; Alghounaim, M.; Jamal, M.H.; Aldei, A.; Mairza, M.J.; et al. Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination. Front. Immunol. 2021, 12, 752233. [Google Scholar] [CrossRef]
- Mitsunaga, T.; Ohtaki, Y.; Seki, Y.; Yoshioka, M.; Mori, H.; Suzuka, M.; Mashiko, S.; Takeda, S.; Mashiko, K. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: A prospective study in Japan. PeerJ 2021, 9, e12316. [Google Scholar] [CrossRef]
- Kageyama, T.; Ikeda, K.; Tanaka, S.; Taniguchi, T.; Igari, H.; Onouchi, Y.; Kaneda, A.; Matsushita, K.; Hanaoka, H.; Nakada, T.-A.; et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin. Microbiol. Infect. 2021, 27, 1861.e1. [Google Scholar] [CrossRef]
- Agarwal, A.; Hegde, A.; Yadav, C.; Ahmad, A.; Manjrekar, P.A.; Srikantiah, R.M. Association of interleukin-6 and myeloperoxidase with insulin resistance in impaired fasting glucose subjects. Indian J. Clin. Biochem. 2017, 32, 33–38. [Google Scholar] [CrossRef] [Green Version]
- Agarwal, A.; Hegde, A.; Yadav, C.; Ahmad, A.; Manjrekar, P.; Rukmini, M.S. Interleukin-6 in impaired fasting glucose. IJBB 2018, 55, 424–428. [Google Scholar] [CrossRef]
- Yamamoto, S.; Maeda, K.; Matsuda, K.; Tanaka, A.; Horii, K.; Okudera, K.; Takeuchi, J.S.; Mizoue, T.; Konishi, M.; Ozeki, M.; et al. COVID-19 breakthrough infection and post-vaccination neutralizing antibody among healthcare workers in a referral hospital in Tokyo: A case-control matching study. Clin. Infect. Dis. 2021, ciab1048, Online aheadof print. [Google Scholar] [CrossRef]
- ADA. Classification and diagnosis of diabetes: Standards of medical care in diabetes—2019. Diabetes Care 2019, 42, S13–S28. [Google Scholar] [CrossRef] [Green Version]
- WHO. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation. 2006. Available online: https://apps.who.int/iris/handle/10665/43588 (accessed on 14 February 2022).
- Takeuchi, J.S.; Fukunaga, A.; Yamamoto, S.; Tanaka, A.; Matsuda, K.; Kimura, M.; Kamikawa, A.; Koto, Y.; Maeda, K.; Ueda, G.; et al. SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2. medRxiv 2021. [Google Scholar] [CrossRef]
- Nomura, Y.; Sawahata, M.; Nakamura, Y.; Kurihara, M.; Koike, R.; Katsube, O.; Hagiwara, K.; Niho, S.; Masuda, N.; Tanaka, T.; et al. Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine. Vaccines 2021, 9, 1042. [Google Scholar] [CrossRef]
- Watanabe, M.; Balena, A.; Tuccinardi, D.; Tozzi, R.; Risi, R.; Masi, D.; Caputi, A.; Rossetti, R.; Spoltore, M.E.; Filippi, V.; et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab. Res. Rev. 2022, 38, e3465. [Google Scholar] [CrossRef]
- Yamamoto, S.; Mizoue, T.; Tanaka, A.; Oshiro, Y.; Inamura, N.; Konishi, M.; Ozeki, M.; Miyo, K.; Sugiura, W.; Sugiyama, H.; et al. Sex–associated differences between body mass index and SARS–CoV–2 antibody titers following the BNT162b2 vaccine among 2,435 healthcare workers in Japan. medRxiv 2021. [Google Scholar] [CrossRef]
- Yamamoto, S.; Tanaka, A.; Ohmagari, N.; Yamaguchi, K.; Ishitsuka, K.; Morisaki, N.; Kojima, M.; Nishikimi, A.; Tokuda, H.; Inoue, M.; et al. Use of heat-not-burn tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers. medRxiv 2021. [Google Scholar] [CrossRef]
- Harrell, F.E. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis; Springer: Berlin/Heidelberg, Germany, 2015. [Google Scholar]
- Karamese, M.; Tutuncu, E.E. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. J. Med. Virol. 2022, 94, 173–177. [Google Scholar] [CrossRef]
- Van Praet, J.T.; Vandecasteele, S.; De Roo, A.; Vynck, M.; De Vriese, A.S.; Reynders, M. Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents. J. Infect. Dis. 2021, 224, 1690–1693. [Google Scholar] [CrossRef]
- Tanaka, T.; Narazaki, M.; Kishimoto, T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect Biol. 2014, 6, a016295. [Google Scholar] [CrossRef]
- Tan, A.T.; Linster, M.; Tan, C.W.; Le Bert, N.; Chia, W.N.; Kunasegaran, K.; Zhuang, Y.; Tham, C.Y.L.; Chia, A.; Smith, G.J.D.; et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021, 34, 108728. [Google Scholar] [CrossRef]
Characteristics | Normoglycemia (N = 884) | IFG (N = 48) | Diabetes (N = 21) |
---|---|---|---|
Age (mean ± SD, year) | 31.4 ± 12.0 | 44.2 ± 12.3 | 43.8 ± 12.4 |
Men (%) | 29.2 | 62.5 | 52.4 |
Body mass index (mean ± SD, kg/m2) | 21.4 ± 3.1 | 24.2 ± 3.9 | 25.5 ± 3.9 |
Smoker (%) | 4.2 | 6.2 | 14.3 |
Alcohol drinker (≥1 go/day, %) | 10.5 | 27.1 | 9.5 |
Hypertension (%) | 6.4 | 37.5 | 52.4 |
Interval between the 2nd dose of vaccine and antibody test [median (IQR), days] | 67 (61 to 70) | 68.5 (62.5 to 71) | 69 (66 to 71) |
SARS-CoV-2 Spike IgG Antibodies | ||
---|---|---|
GMT (95% CI) | Ratio of Mean (95% CI) | |
Normoglycemia | 5530 (5301–5770) | 1.00 (Reference) |
IFG | 4374 (3337–5733) | 0.79 (0.60–1.04) |
Diabetes | 3353 (2348–4790) | 0.60 (0.42–0.87) |
p§ trend | <0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Islam, Z.; Yamamoto, S.; Mizoue, T.; Tanaka, A.; Oshiro, Y.; Inamura, N.; Konishi, M.; Ozeki, M.; Sugiura, W.; Ohmagari, N. Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan. Vaccines 2022, 10, 776. https://doi.org/10.3390/vaccines10050776
Islam Z, Yamamoto S, Mizoue T, Tanaka A, Oshiro Y, Inamura N, Konishi M, Ozeki M, Sugiura W, Ohmagari N. Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan. Vaccines. 2022; 10(5):776. https://doi.org/10.3390/vaccines10050776
Chicago/Turabian StyleIslam, Zobida, Shohei Yamamoto, Tetsuya Mizoue, Akihito Tanaka, Yusuke Oshiro, Natsumi Inamura, Maki Konishi, Mitsuru Ozeki, Wataru Sugiura, and Norio Ohmagari. 2022. "Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan" Vaccines 10, no. 5: 776. https://doi.org/10.3390/vaccines10050776
APA StyleIslam, Z., Yamamoto, S., Mizoue, T., Tanaka, A., Oshiro, Y., Inamura, N., Konishi, M., Ozeki, M., Sugiura, W., & Ohmagari, N. (2022). Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan. Vaccines, 10(5), 776. https://doi.org/10.3390/vaccines10050776